Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT

Ferdinando Calabria, Agostino Chiaravalloti, Barbara Di Pietro, Cristina Grasso, Orazio Schillaci

Research output: Contribution to journalArticlepeer-review


The objective of this study was to give an overview of the potential clinical utility of [ 18F]-L-dihydroxyphenylalanine ( 18F-DOPA) PET and PET/CT for imaging of brain tumors. Review articles and reference lists were used to supplement the search findings. 18F-DOPA has been investigated as a PET tracer for primary brain tumors, metastases of somatic cancer, and evaluation of relapse of pathology in patients with brain tumor after surgery and/or radiotherapy on the basis of enhanced cell proliferation. Available studies have provided encouraging preliminary results for diagnosis of brain tumors and relapse after surgery/radiotherapy. In the brain, excellent discrimination between tumor and normal tissue can be achieved because of the low physiological uptake of 18F-DOPA and the high ratio between tumor and normal hemispheric tissue. Information on evaluation of brain metastases is limited but encouraging. PET and PET/CT with 18F-DOPA are useful in diagnosing primary brain tumors and should be recommended in the diagnosis of relapse of disease after surgical treatment and/or radiotherapy. Semiquantitative analysis could improve diagnosis while correlative imaging with MRI is essential. Limits are due to low knowledge of potential pitfalls.

Original languageEnglish
Pages (from-to)563-570
Number of pages8
JournalNuclear Medicine Communications
Issue number6
Publication statusPublished - Jun 2012


  • [ F]-L-dihydroxyphenylalanine
  • brain metastases
  • brain tumors
  • molecular imaging
  • PET/CT
  • recurrence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT'. Together they form a unique fingerprint.

Cite this